Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 plus azacitidine in low- and intermediate-risk myelodysplastic syndromes
ChiCTR2600126531Phase 2Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim and azacitidine in myelodysplastic syndrome (MDS), sponsored by Fujian Provincial Hospital. Primary endpoints: Complete or major platelet response rate within 4 cycles and Incidence rate of adverse drug reactions. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
romiplostimazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600126531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126531.